Education
About Us
Working with TipRanks
Follow Us
Mainz Biomed B.V. (MYNZ)
NASDAQ:MYNZ
MYNZ Stock Chart & Stats
$1.16
-$0.30(-6.42%)
At close: 4:00 PM EST
$1.16
-$0.30(-6.42%)
Day’s Range― - ―
52-Week Range$0.92 - $8.20
Previous CloseN/A
Volume20.13K
Average Volume (3M)350.23K
Market Cap
$10.60M
Enterprise Value$0.00
Total Cash (Recent Filing)$1.91M
Total Debt (Recent Filing)$3.09M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Apr 14, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.65
Shares Outstanding9,060,142
10 Day Avg. Volume923,862
30 Day Avg. Volume350,228
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.69
Price to Sales (P/S)4.68
P/FCF Ratio-0.24
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial StrategyMainz Biomed's decentralized commercial strategy includes partnering with lab groups to reduce marketing and infrastructure expenses, and gain access to large physician networks.
Market OpportunityExisting tests with a similar format, such as Cologuard, have achieved commercial success with over $2B in annual sales, presenting an opportunity for Mainz Biomed to capture share.
Product PerformanceMainz Biomed's Next Generation Test leverages mRNA biomarkers to expand the ability to detect pre-cancerous advanced adenomas, enabling prevention of CRC.
Bears Say
Feasibility StudyThe feasibility study seeks to evaluate the panel and machine learning algorithm to determine sensitivity, specificity, and consistency, which presents potential uncertainty.
Unmet NeedPancreatic cancer detection is an area of significant unmet need, with 67k cases in the US each year, the majority of which are caught at Stage 4.
Mainz Biomed B.V. News
MYNZ FAQ
What was Mainz Biomed B.V.’s price range in the past 12 months?
Mainz Biomed B.V. lowest stock price was $0.92 and its highest was $8.20 in the past 12 months.
What is Mainz Biomed B.V.’s market cap?
Mainz Biomed B.V.’s market cap is $10.60M.
When is Mainz Biomed B.V.’s upcoming earnings report date?
Mainz Biomed B.V.’s upcoming earnings report date is Apr 14, 2026 which is in 90 days.
How were Mainz Biomed B.V.’s earnings last quarter?
Mainz Biomed B.V. released its earnings results on Sep 03, 2025. The company reported -$2.65 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.65.
Is Mainz Biomed B.V. overvalued?
According to Wall Street analysts Mainz Biomed B.V.’s price is currently Overvalued.
Does Mainz Biomed B.V. pay dividends?
Mainz Biomed B.V. does not currently pay dividends.
What is Mainz Biomed B.V.’s EPS estimate?
Mainz Biomed B.V.’s EPS estimate is -1.01.
How many shares outstanding does Mainz Biomed B.V. have?
Mainz Biomed B.V. has 9,060,142 shares outstanding.
What happened to Mainz Biomed B.V.’s price movement after its last earnings report?
Mainz Biomed B.V. reported an EPS of -$2.65 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.775%.
Which hedge fund is a major shareholder of Mainz Biomed B.V.?
Currently, no hedge funds are holding shares in MYNZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mainz Biomed B.V.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Technical Analysis
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
5.38% Other Institutional Investors
94.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---